Abstracts mitral replacement. To assess how experience may impact the efficacy of mitral repair on patients with increasing complexity, we examined 941 consecutive patients who underwent mitral valve repair from July 1992 to January 2000. METHODS: All patients underwent primary mitral repair for regurgitation. Of the 941 patients, 750 had their operations between July 1992 and December 1998 (A), and 191 between January 1999 and January 2000 (B). Outcomes were analyzed for incidences of STS co-morbid criteria and concomitant cardiac procedures (valvular, arch, or CABG) performed during the study periods. RESULTS: For the 941 patients, 530 (56%) were male, patient age was 62 ± 13.3 years (range 20-88). Group A included 204/750 with comorbidities (27.2%) vs. 176/191 (92%) in Group B (p < 0.0001). Overall incidence of concomitant procedures in the 2 groups was similar [58% A, 57% B (p = NS)]. Cross clamp times were reduced from 104.9 ± 12.5 min in Group A to 84.9 ± 10.4 min in Group B (p < 0.0001). There were no differences in atrial fibrillation between groups (27.6% A, 28.3% B). There were a total of 53 30-day mortalities (5.6%), with a trend towards reduced mortality in Group B [6.1% Group A, 3.7% Group B (p = 0.19)]. Average LOS decreased from 12.2 ± 14.9 days in Group A to 8.7 ± 8.5 days in Group B (p = 0.02). CONCLUSIONS: Mitral valve repair remains a safe and effective treatment for patients with mitral regurgitation including those with comorbid conditions and those requiring concomitant cardiac procedures. As experience is gained with reparative techniques, surgeons may be more willing to safely apply them to an increasingly complex patient population. 
PCV8

CHOICE OF FIRST-LINE TREATMENT FOR
OBJECTIVES:
This study sets out to explore the adherence to British Hypertension Guidelines in choosing firstline treatment for blood pressure by general practitioners (GPs) in the UK. These currently recommend thiazide diuretics as the preferred choice and beta-blockers as an alternative initial treatment for most patients.
METHODS:
The data on choice of blood pressure treatment recorded at first diagnosis of hypertension were obtained from a UK GP computer database, IMS Disease Analyzer-Mediplus. The records covered the 1-year period March 2002 to February 2003. The database holds the records of 564 GPs and 948,958 registered patients. RESULTS: Of 8,540 patients with at least three months history on the database and a new diagnosis of hypertension within the year of analysis, initial treatment was as follows: 36.5% thiazide diuretic; 22.4% betablocker; 17.8% ACE inhibitor; 10.1% calcium channel blocker; 4.0% angiotensin-2-receptor antagonist; 2.1% alpha-blocker. Of those, 16.4% were not started immediately on antihypertensive therapy. Of those that did, 4.6% received first treatment as a combination of two drugs (hence the total figures do not add up to 100%). CONCLUSIONS: This study suggests that first-line treatment is often using a drug that is not in accord with current National policy as only 58.9% were started on recommended first-line therapy. Choices from other drug classes tend to be more expensive, and there is less evidence of benefit. In particular the 4.6% starting treatment with combination therapy appears at odds with the policy to start with a single agent. Co-morbidity such as diabetes or bladder outflow obstruction may explain the choice of other agents; for example angiotensin-inhibiting drugs in diabetes, but the prevalence of these conditions is not sufficient to explain this variation from the guidelines. This choice of drugs may reflect heavy marketing of these newer products rather than evidence-based medicine.
